Levels of the protein TXNRD1 are reduced in the blood of people with idiopathic pulmonary arterial hypertension (IPAH), suggesting it may be useful as a potential diagnostic marker or treatment target in IPAH, according to a new study. “This study is the first report to prove that TXNRD1 may…
News
The U.S. Food and Drug Administration (FDA) has approved LungFit PH, Beyond Air‘s device to administer nitric oxide therapy, to treat persistent pulmonary hypertension of the newborn (PPHN). “The FDA approval of LungFit PH enables a new era of nitric oxide therapy and marks a pivotal event for…
The leading causes of death among people with pulmonary hypertension (PH) differ by PH type, a Japanese study has found. When categorized using the World Health Organization (WHO) PH classification, those in group 1 died mostly from PH itself, those in group 3 died more often from…
An under-the-skin infusion of a protein called netrin-1 — originally found to regulate nervous system development — shows promise for lessening pulmonary hypertension (PH), a mouse study suggests. Additionally, the scientists found that three small peptides derived from netrin-1 also are a potential therapy for easing PH. The…
Seven members of the pulmonary hypertension (PH) community — ranging from an 11-year-old advocate diagnosed in infancy to a physician who has led clinical trials, to a longtime fundraiser who’s a retired teacher — have been honored for their dedication and service by the Pulmonary Hypertension Association (PHA).
Pulmonary hypertension (PH) induced in response to exercise may be linked to a higher risk of cardiovascular (CV) disease in patients with human immunodeficiency virus (HIV), a small study found. Those with a higher CV risk had fewer CD4 T-cells, a type of immune cell that drops to extremely…
Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in multiple rodent models of pulmonary arterial hypertension (PAH), a study reported. The study, “Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension,” was published in…
A research form of Keros Therapeutics’ investigational therapy KER-012, called RKER-012, reduced lung inflammation and scarring (fibrosis) in a rat model of pulmonary arterial hypertension (PAH). The therapy also prevented an increase in the levels of a heart damage marker, the company announced in a press release. The…
Seralutinib (GB002), an investigational inhaled treatment for pulmonary arterial hypertension (PAH), effectively treated severe disease in two animal models, a study demonstrated. Further, when compared directly, inhaled seralutinib showed greater efficacy than imatinib, an approved cancer therapy also being investigated for PAH. Gossamer Bio, seralutinib’s developer, now is testing…
Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH), a new study reports. “The promising results of our research may form the basis for a more detailed study of the effects of CBD or its derivatives on PH, especially…
Despite recent advances in care, mortality while in the intensive care unit (ICU) and up to one year thereafter remains high among people with pulmonary arterial hypertension (PAH), a new study reports. Risk factors for mortality one year after ICU discharge included low blood sodium, raised pro-B-type natriuretic peptide…
High scores on a measure known as H2FPEF — which reflect an increased probability of dysfunction of the left ventricle (LV) of the heart — were associated with signs of LV impairment and a worse prognosis in patients with idiopathic pulmonary arterial hypertension (IPAH), a study found. Patients with…
